What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables

Immunotherapy targeting the PD-1–PD-L1 axis yielded good results in treating different immunologically ‘‘hot’’ tumors. A phase II study revealed good therapeutic activity of pembrolizumab in selected prostatic carcinoma (PC)-patients. We performed a systematic literature review (PRISMA guidelines),...

Descripción completa

Detalles Bibliográficos
Autores principales: Palicelli, Andrea, Bonacini, Martina, Croci, Stefania, Magi-Galluzzi, Cristina, Cañete-Portillo, Sofia, Chaux, Alcides, Bisagni, Alessandra, Zanetti, Eleonora, De Biase, Dario, Melli, Beatrice, Sanguedolce, Francesca, Ragazzi, Moira, Bonasoni, Maria Paola, Soriano, Alessandra, Ascani, Stefano, Zizzo, Maurizio, Castro Ruiz, Carolina, De Leo, Antonio, Giordano, Guido, Landriscina, Matteo, Carrieri, Giuseppe, Cormio, Luigi, Berney, Daniel M., Athanazio, Daniel, Gandhi, Jatin, Cavazza, Alberto, Santandrea, Giacomo, Tafuni, Alessandro, Zanelli, Magda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625301/
https://www.ncbi.nlm.nih.gov/pubmed/34831389
http://dx.doi.org/10.3390/cells10113166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625301/
https://www.ncbi.nlm.nih.gov/pubmed/34831389
http://dx.doi.org/10.3390/cells10113166

Ejemplares similares